\documentclass[11pt]{article}

% Packages
\usepackage[utf8]{inputenc}
\usepackage[margin=1in]{geometry}
\usepackage{booktabs}
\usepackage{longtable}
\usepackage{array}
\usepackage{multirow}
\usepackage{hyperref}
\usepackage{amsmath}
\usepackage{graphicx}
\usepackage{lscape}

% Title information
\title{Online Supplementary Material to: Cost-effectiveness analysis of non-surgical periodontal treatment for preventing strokes and myocardial infarction in the UK}
\author{}
\date{}

\begin{document}

\maketitle

\section{Consolidated Health Economic Evaluation Reporting Standards 2022 Checklist}

\begin{longtable}{p{0.15\textwidth}p{0.05\textwidth}p{0.65\textwidth}p{0.10\textwidth}}
\caption{CHEERS 2022 Checklist} \label{tab:cheers} \\
\toprule
\textbf{Topic} & \textbf{No.} & \textbf{Item} & \textbf{Location} \\
\midrule
\endfirsthead

\multicolumn{4}{c}%
{{\tablename\ \thetable{} -- continued from previous page}} \\
\toprule
\textbf{Topic} & \textbf{No.} & \textbf{Item} & \textbf{Location} \\
\midrule
\endhead

\midrule
\multicolumn{4}{r}{{Continued on next page}} \\
\endfoot

\bottomrule
\endlastfoot

\multicolumn{4}{l}{\textbf{Title}} \\
Title & 1 & Identify the study as an economic evaluation and specify the interventions being compared. & \\
\multicolumn{4}{l}{\textbf{Abstract}} \\
Abstract & 2 & Provide a structured summary that highlights context, key methods, results, and alternative analyses. & \\
\multicolumn{4}{l}{\textbf{Introduction}} \\
Background and objectives & 3 & Give the context for the study, the study question, and its practical relevance for decision making in policy or practice. & \\
\multicolumn{4}{l}{\textbf{Methods}} \\
Health economic analysis plan & 4 & Indicate whether a health economic analysis plan was developed and where available. & \\
Study population & 5 & Describe characteristics of the study population (such as age range, demographics, socioeconomic, or clinical characteristics). & \\
Setting and location & 6 & Provide relevant contextual information that may influence findings. & \\
Comparators & 7 & Describe the interventions or strategies being compared and why chosen. & \\
Perspective & 8 & State the perspective(s) adopted by the study and why chosen. & \\
Time horizon & 9 & State the time horizon for the study and why appropriate. & \\
Discount rate & 10 & Report the discount rate(s) and reason chosen. & \\
Selection of outcomes & 11 & Describe what outcomes were used as the measure(s) of benefit(s) and harm(s). & \\
Measurement of outcomes & 12 & Describe how outcomes used to capture benefit(s) and harm(s) were measured. & \\
Valuation of outcomes & 13 & Describe the population and methods used to measure and value outcomes. & \\
Measurement and valuation of resources and costs & 14 & Describe how costs were valued. & \\
Currency, price date, and conversion & 15 & Report the dates of the estimated resource quantities and unit costs, plus the currency and year of conversion. & \\
Rationale and description of model & 16 & If modelling is used, describe in detail and why used. Report if the model is publicly available and where it can be accessed. & \\
Analytics and assumptions & 17 & Describe any methods for analysing or statistically transforming data, any extrapolation methods, and approaches for validating any model used. & \\
Characterising heterogeneity & 18 & Describe any methods used for estimating how the results of the study vary for subgroups. & \\
Characterising distributional effects & 19 & Describe how impacts are distributed across different individuals or adjustments made to reflect priority populations. & \\
Characterising uncertainty & 20 & Describe methods to characterise any sources of uncertainty in the analysis. & \\
Approach to engagement with patients and others affected by the study & 21 & Describe any approaches to engage patients or service recipients, the general public, communities, or stakeholders (such as clinicians or payers) in the design of the study. & \\
\multicolumn{4}{l}{\textbf{Results}} \\
Study parameters & 22 & Report all analytic inputs (such as values, ranges, references) including uncertainty or distributional assumptions. & \\
Summary of main results & 23 & Report the mean values for the main categories of costs and outcomes of interest and summarise them in the most appropriate overall measure. & \\
Effect of uncertainty & 24 & Describe how uncertainty about analytic judgments, inputs, or projections affect findings. Report the effect of choice of discount rate and time horizon, if applicable. & \\
Effect of engagement with patients and others affected by the study & 25 & Report on any difference patient/service recipient, general public, community, or stakeholder involvement made to the approach or findings of the study & \\
\multicolumn{4}{l}{\textbf{Discussion}} \\
Study findings, limitations, generalisability, and current knowledge & 26 & Report key findings, limitations, ethical or equity considerations not captured, and how these could affect patients, policy, or practice. & \\
\multicolumn{4}{l}{\textbf{Other relevant information}} \\
Source of funding & 27 & Describe how the study was funded and any role of the funder in the identification, design, conduct, and reporting of the analysis & \\
Conflicts of interest & 28 & Report authors conflicts of interest according to journal or International Committee of Medical Journal Editors requirements. & \\

\end{longtable}

\clearpage

\section{Model Parameters And Values}

\begin{longtable}{p{0.35\textwidth}p{0.15\textwidth}p{0.35\textwidth}}
\caption{All model parameters and values} \label{tab:parameters} \\
\toprule
\textbf{Parameter} & \textbf{Value} & \textbf{Reference} \\
\midrule
\endfirsthead

\multicolumn{3}{c}%
{{\tablename\ \thetable{} -- continued from previous page}} \\
\toprule
\textbf{Parameter} & \textbf{Value} & \textbf{Reference} \\
\midrule
\endhead

\midrule
\multicolumn{3}{r}{{Continued on next page}} \\
\endfoot

\bottomrule
\endlastfoot

\multicolumn{3}{l}{\textbf{Baseline Hazards}} \\
Base state stroke hazard & 0.0336 & [1] \\
Base state CHD hazard & 0.0463 & [2] \\
Background death hazard & 0.0126 & [3] \\
\multicolumn{3}{l}{\textbf{Case Fatality Rates}} \\
Stroke fatality & 0.1 & [4] \\
CHD fatality & 0.14 & [5] \\
\multicolumn{3}{l}{\textbf{Hazard multipliers by state}} \\
Stroke Post-Stroke Y1 & 1.36 & [6] \\
Stroke Post-Stroke Y2 & 1.36 & [6] \\
CHD Post CHD Y1 & 1.19 & [6] \\
CHD Post CHD Y2 & 1.19 & [6] \\
Stroke Post Both Y1 & 1.94 & [6] \\
Stroke Post Both Y2 & 1.94 & [6] \\
CHD Post Both Y1 & 1.94 & [6] \\
CHD Post Both Y2 & 1.94 & [6] \\
\multicolumn{3}{l}{\textbf{Utilities}} \\
Base & 0.83 & [7] \\
Post-Stroke Y1 & 0.7 & [7] \\
Post-Stroke Y2 & 0.68 & [7] \\
Post CHD Y1 & 0.77 & [7] \\
Post CHD Y2 & 0.74 & [7] \\
Post Both Y1 & 0.54 & Multiplicative approach \\
Post Both Y2 & 0.50 & Multiplicative approach \\
Dead & 0 & \\
Disutility of stroke event & $-$0.59 & [8] \\
Disutility of CHD event & $-$0.03 & [9] \\

\end{longtable}

\clearpage

\section{Transition Matrices}

\begin{landscape}
\begin{table}[ht]
\centering
\caption{Base Markov model transition matrices}
\label{tab:transitions}
\small
\begin{tabular}{lcccccccc}
\toprule
 & \textbf{Base} & \textbf{Post-Stroke} & \textbf{Post-Stroke} & \textbf{Post-CHD} & \textbf{Post-CHD} & \textbf{Post-Both} & \textbf{Post-Both} & \textbf{Dead} \\
 & \textbf{(no CVD)} & \textbf{(Y1)} & \textbf{(Y2)} & \textbf{(Y1)} & \textbf{(Y2)} & \textbf{(Y1)} & \textbf{(Y2)} & \textbf{(absorbing)} \\
\midrule
\multicolumn{9}{l}{\textbf{Base Arm}} \\
Base (no prior CVD) & 0.912 & 0.028 & 0.000 & 0.037 & 0.000 & 0.001 & 0.000 & 0.022 \\
Post-Stroke (Y1) & 0.000 & 0.000 & 0.987 & 0.000 & 0.000 & 0.000 & 0.000 & 0.013 \\
Post-Stroke (Y2) & 0.000 & 0.038 & 0.901 & 0.000 & 0.000 & 0.038 & 0.000 & 0.023 \\
Post-CHD (Y1) & 0.000 & 0.000 & 0.000 & 0.000 & 0.987 & 0.000 & 0.000 & 0.013 \\
Post-CHD (Y2) & 0.000 & 0.000 & 0.000 & 0.044 & 0.904 & 0.029 & 0.000 & 0.023 \\
Post-Both (Y1) & 0.000 & 0.000 & 0.000 & 0.000 & 0.000 & 0.000 & 0.987 & 0.013 \\
Post-Both (Y2) & 0.000 & 0.051 & 0.000 & 0.068 & 0.000 & 0.004 & 0.846 & 0.031 \\
Dead (absorbing) & 0.000 & 0.000 & 0.000 & 0.000 & 0.000 & 0.000 & 0.000 & 1.000 \\
\midrule
\multicolumn{9}{l}{\textbf{Treated Arm}} \\
Base (no prior CVD) & 0.938 & 0.016 & 0.000 & 0.027 & 0.000 & 0.000 & 0.000 & 0.019 \\
Post-Stroke (Y1) & 0.000 & 0.000 & 0.987 & 0.000 & 0.000 & 0.000 & 0.000 & 0.013 \\
Post-Stroke (Y2) & 0.000 & 0.021 & 0.932 & 0.000 & 0.000 & 0.027 & 0.000 & 0.019 \\
Post-CHD (Y1) & 0.000 & 0.000 & 0.000 & 0.000 & 0.987 & 0.000 & 0.000 & 0.013 \\
Post-CHD (Y2) & 0.000 & 0.000 & 0.000 & 0.032 & 0.933 & 0.016 & 0.000 & 0.020 \\
Post-Both (Y1) & 0.000 & 0.000 & 0.000 & 0.000 & 0.000 & 0.000 & 0.987 & 0.013 \\
Post-Both (Y2) & 0.000 & 0.029 & 0.000 & 0.050 & 0.000 & 0.002 & 0.895 & 0.024 \\
Dead (absorbing) & 0.000 & 0.000 & 0.000 & 0.000 & 0.000 & 0.000 & 0.000 & 1.000 \\
\bottomrule
\end{tabular}
\end{table}
\end{landscape}

\clearpage

\section{Cost Associated With Periodontal Disease}

\begin{table}[ht]
\centering
\caption{Full breakdown of periodontal costs}
\label{tab:pd_costs}
\begin{tabular}{lrrrrr}
\toprule
\textbf{Procedure} & \textbf{Labour} & \textbf{Laboratory} & \textbf{Total} & \textbf{Expected} & \textbf{Expected cost} \\
 & \textbf{Cost (\pounds)} & \textbf{Cost (\pounds)} & \textbf{Cost (\pounds)} & \textbf{amount/cycle} & \textbf{per cycle (\pounds)} \\
\midrule
Initial periodontal treatment & 530.75 & - & 530.75 & 0.1 & 53.07 \\
Periodontal re-treatment & 265.37 & - & 265.37 & 1 & 265.37 \\
Periodontal maintenance & 35.90 & - & 35.90 & 0.5 & 17.95 \\
Extraction & 71.79 & - & 71.79 & 1 & 71.79 \\
Resin-bonded bridge & 285.89 & 96.15 & 382.04 & 1 & 382.04 \\
Removable partial denture & 356.40 & 128.20 & 484.60 & 1 & 484.60 \\
\bottomrule
\end{tabular}
\end{table}

\section{Costs Associated With Markov States}

Costs sourced from Patel et al. (2020) \cite{patel2020} were multiplied using a 2014/2015 GPD inflator value of 1.3396 to get our 2024 deterministic value. A value of 1.1706 was used for costs sourced from Morton et al. (2024) \cite{morton2024}.

\begin{longtable}{p{0.15\textwidth}p{0.15\textwidth}p{0.15\textwidth}p{0.40\textwidth}p{0.08\textwidth}}
\caption{Breakdown of costs per Markov state} \label{tab:state_costs} \\
\toprule
\textbf{State} & \textbf{Value from} & \textbf{Deterministic} & \textbf{Description} & \textbf{Ref.} \\
 & \textbf{source (year)} & \textbf{2024 Value (\pounds)} & & \\
\midrule
\endfirsthead

\multicolumn{5}{c}%
{{\tablename\ \thetable{} -- continued from previous page}} \\
\toprule
\textbf{State} & \textbf{Value from} & \textbf{Deterministic} & \textbf{Description} & \textbf{Ref.} \\
 & \textbf{source (year)} & \textbf{2024 Value (\pounds)} & & \\
\midrule
\endhead

\midrule
\multicolumn{5}{r}{{Continued on next page}} \\
\endfoot

\bottomrule
\endlastfoot

Base & 0 & 0 & Base state costs were assumed to be zero as we are evaluating the costs of CVD events and individuals enter CVD free. & N/a \\
Post Stroke Y1 & 15,577 (2014) & 20,866.95 & The mean NHS \& PSS first year cost for an individual aged 65-74 years old was used here. & [10] \\
Post Stroke Y2 & 5,761(2014) & 7,717.44 & The mean NHS \& PSS first year cost for an individual aged 65-74 years old was used here. & [10] \\
Post CHD Y1 & 4,705.45 (2020) & 6,303.42 & Healthcare costs for an individual in the first six months after a MI. & [9] \\
Post CHD Y2 & 1,015.21 (2020) & 1,359.98 & Healthcare costs for an individual per year after a MI. & [9] \\
Post Both Y1 & 15,577 (2014) & 20,866.95 & The highest cost of the two events was selected to model for post-both in order to capture an accurate value in the absence of evidence. & [10] \\
Post Both Y2 & 5,761(2014) & 7,717.44 & The highest cost of the two events was selected to model for post-both in order to capture an accurate value in the absence of evidence. & [10] \\
Dead & 0 & 0 & - & N/a \\
Stroke event (one-off) & 3,061.20 (2003) & 5,240.77 & Cost to the NHS over 5 years was \pounds15,306, which we divided by 5 to give the single year cost. The cost inflator value was 1.712. & [11] \\
CHD event (one-off) & 2,047.31 (2020) & 2,396.58 & Direct healthcare costs of the acute event. & [12] \\

\end{longtable}

\clearpage

\section{Sensitivity Analysis}

\begin{landscape}
\begin{longtable}{p{0.25\textwidth}p{0.10\textwidth}p{0.15\textwidth}p{0.12\textwidth}p{0.08\textwidth}p{0.08\textwidth}}
\caption{Parameters and related values used in sensitivity analysis} \label{tab:sensitivity} \\
\toprule
\textbf{Parameter} & \textbf{Deterministic} & \textbf{CI for one-way} & \textbf{Parameter} & \multicolumn{2}{c}{\textbf{Probabilistic sensitivity}} \\
 & \textbf{Value} & \textbf{sensitivity analysis} & \textbf{Distribution} & \textbf{analysis} & \textbf{analysis} \\
 & & & & $\alpha$ & $\beta$ \\
\midrule
\endfirsthead

\multicolumn{6}{c}%
{{\tablename\ \thetable{} -- continued from previous page}} \\
\toprule
\textbf{Parameter} & \textbf{Deterministic} & \textbf{CI for one-way} & \textbf{Parameter} & \multicolumn{2}{c}{\textbf{Probabilistic sensitivity}} \\
 & \textbf{Value} & \textbf{sensitivity analysis} & \textbf{Distribution} & \textbf{analysis} & \textbf{analysis} \\
 & & & & $\alpha$ & $\beta$ \\
\midrule
\endhead

\midrule
\multicolumn{6}{r}{{Continued on next page}} \\
\endfoot

\bottomrule
\endlastfoot

\multicolumn{6}{l}{\textbf{Baseline Hazards}} \\
Base state stroke hazard & 0.0336 & (0.030-0.037) & Beta & 4 & 96 \\
Base state CHD hazard & 0.0463 & (0.042-0.51) & Beta & 12.5 & 258 \\
Background death hazard & 0.0126 & (0.011-0.014) & Beta & 1.7 & 132.5 \\
\multicolumn{6}{l}{\textbf{Case Fatality Rates}} \\
Stroke fatality & 0.1 & (0.09-0.11) & Beta & 1 & 3 \\
CHD fatality & 0.14 & (0.126-0.154) & Beta & 1 & 4 \\
\multicolumn{6}{l}{\textbf{Hazard Multipliers by state}} \\
Stroke Post-Stroke Y1 & 1.36 & (1.03-1.80) & Beta & 1.19 & 1.58 \\
Stroke Post-Stroke Y2 & 1.36 & (1.03-1.80) & Beta & 1.19 & 1.58 \\
CHD Post CHD Y1 & 1.19 & (1.05-1.34) & Beta & 1.37 & 1.47 \\
CHD Post CHD Y2 & 1.19 & (1.05-1.34) & Beta & 1.37 & 1.47 \\
Stroke Post Both Y1 & 1.94 & (1.23-3.04) & Beta & 1.045 & 1.619 \\
Stroke Post Both Y2 & 1.94 & (1.23-3.04) & Beta & 1.045 & 1.619 \\
CHD Post Both Y1 & 1.94 & (1.23-3.04) & Beta & 1.045 & 1.619 \\
CHD Post Both Y2 & 1.94 & (1.23-3.04) & Beta & 1.045 & 1.619 \\
\multicolumn{6}{l}{\textbf{Treatment Effects}} \\
Stroke & 0.55 & (0.29-0.81) & Beta & 1.59 & 1.16 \\
CHD & 0.7 & (0.44-0.95) & Beta & 2.15 & 2.3 \\
\multicolumn{6}{l}{\textbf{Utilities}} \\
Post-Stroke Y1 & 0.70 & (0.65-0.76) & Beta & 11.1 & 4.8 \\
Post-Stroke Y2 & 0.68 & (0.64-0.74) & Beta & 12.1 & 5.6 \\
Post CHD Y1 & 0.77 & (0.73-0.81) & Beta & 420 & 125.5 \\
Post CHD Y2 & 0.74 & (0.70-0.78) & Beta & 16.7 & 5.9 \\
Post Both Y1 & 0.54 & (0.49-0.59) & Beta & 10.5 & 9 \\
Post Both Y2 & 0.50 & (0.45-0.54) & Beta & 10.75 & 10.61 \\
Dead & 0 & - & Beta & - & - \\
Stroke event & $-$0.59 & ($-$0.885- $-$0.295) & Beta & 5 & 5 \\
CHD event & $-$0.03 & ($-$0.045- $-$0.015) & Beta & 5 & 5 \\
\multicolumn{6}{l}{\textbf{Costs (\pounds)}} \\
Base & 0 & - & Gamma & - & - \\
Post Stroke Y1 & 20,866.95 & (19,748.38-21,985.52) & Gamma & 1337.4 & 15.61 \\
Post Stroke Y2 & 7,717.44 & (5,886.20-9,550.01) & Gamma & 68.2 & 113.2 \\
Post CHD Y1 & 6,303.42 & (6,082.51-6,524.33) & Gamma & 3,127.72 & 2.01 \\
Post CHD Y2 & 1,359.98 & (1,024.37-1,695.59) & Gamma & 63.17 & 21.56 \\
Post Both Y1 & 20,866.95 & (19,748.38-21,985.52) & Gamma & 1337.4 & 15.61 \\
Post Both Y2 & 7,717.44 & (5,886.20-9,550.01) & Gamma & 68.2 & 113.2 \\
Dead & 0 & - & Gamma & - & - \\
Stroke Event & 5,240.77 & (4,716.69-5,764.85) & Gamma & 25 & 209.63 \\
CHD Event & 2,3996.58 & (2,037.09-2,756.07) & Gamma & 170.6 & 14.05 \\
Per cycle non-periodontal cost & 1,274.82 & - & Gamma & 25 & 50.99 \\

\end{longtable}
\end{landscape}

\clearpage

\section*{References}

\begin{thebibliography}{99}

\bibitem{zemedikun2021}
Zemedikun DT, Chandan JS, Raindi D, et al.
Burden of chronic diseases associated with periodontal diseases: a retrospective cohort study using UK primary care data.
\textit{BMJ Open}. 2021;11(12):e048296.
\href{https://doi.org/10.1136/bmjopen-2020-048296}{doi:10.1136/bmjopen-2020-048296}.

\bibitem{seoane2022}
Seoane T, Bullon B, Fernandez-Riejos P, et al.
Periodontitis and other risk factors related to myocardial infarction and its follow-up.
\textit{J Clin Med}. 2022;11(9):2618.
\href{https://doi.org/10.3390/jcm11092618}{doi:10.3390/jcm11092618}.

\bibitem{ons2025}
Office for National Statistics.
National Life Tables: UK [Internet].
London, England: Office for National Statistics; March 18, 2025.
Accessed October 23, 2025.
Available from: \url{https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables}

\bibitem{morgan2021}
Morgan A, Sinnott SJ, Smeeth L, Minassian C, Quint J.
Concordance in the recording of stroke across UK primary and secondary care datasets: a population-based cohort study.
\textit{BJGP Open}. 2021;5(2):BJGPO.2020.0117.
\href{https://doi.org/10.3399/BJGPO.2020.0117}{doi:10.3399/BJGPO.2020.0117}

\bibitem{allara2025}
Allara E, Shi W, Bolton T, et al.
Burden of cardiovascular diseases in England (2020--24): a national cohort using electronic health records data.
\textit{Lancet Public Health}. 2025;10(11):e943--e954.
\href{https://doi.org/10.1016/S2468-2667(25)00163-X}{doi:10.1016/S2468-2667(25)00163-X}.

\bibitem{danese2021}
Danese MD, Pemberton-Ross P, Catterick D, Villa G.
Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom.
\textit{Eur J Prev Cardiol}. 2021;28(3):335--343.
\href{https://doi.org/10.1177/2047487319899212}{doi:10.1177/2047487319899212}.

\bibitem{lui2023}
Lui JN, Williams C, Keng MJ, et al; REVEAL Collaborative Group.
Impact of new cardiovascular events on quality of life and hospital costs in people with cardiovascular disease in the United Kingdom and United States.
\textit{J Am Heart Assoc}. 2023;12(19):e030766.
\href{https://doi.org/10.1161/JAHA.123.030766}{doi:10.1161/JAHA.123.030766}.

\bibitem{thom2019}
Thom HH, Hollingworth W, Sofat R, et al.
Directly acting oral anticoagulants for the prevention of stroke in atrial fibrillation in England and Wales: cost-effectiveness model and value of information analysis.
\textit{MDM Policy Pract}. 2019;4(2):2381468319866828.
\href{https://doi.org/10.1177/2381468319866828}{doi:10.1177/2381468319866828}.

\bibitem{morton2024}
Morton JI, Marquina C, Lloyd M, Watts GF, Zoungas S, Liew D, Ademi Z.
Lipid-lowering strategies for primary prevention of coronary heart disease in the UK: a cost-effectiveness analysis.
\textit{Pharmacoeconomics}. 2024;42(1):91--107.
\href{https://doi.org/10.1007/s40273-023-01306-2}{doi:10.1007/s40273-023-01306-2}.

\bibitem{patel2020}
Patel A, Berdunov V, Quayyum Z, King D, Knapp M, Wittenberg R.
Estimated societal costs of stroke in the UK based on a discrete event simulation.
\textit{Age Ageing}. 2020;49(2):270--276.
\href{https://doi.org/10.1093/ageing/afz162}{doi:10.1093/ageing/afz162}.

\bibitem{youman2003}
Youman P, Wilson K, Harraf F, Kalra L.
The economic burden of stroke in the United Kingdom.
\textit{Pharmacoeconomics}. 2003;21:43--50.
\href{https://doi.org/10.2165/00019053-200321001-00005}{doi:10.2165/00019053-200321001-00005}.

\bibitem{nhs2021}
National Health Service.
2020/21 National Cost Collection for the NHS.
Available from: \url{https://www.england.nhs.uk/costing-in-the-nhs/national-cost-collection/}.
Accessed December 1, 2025.

\end{thebibliography}

\end{document}
